No products in the cart.
Pre-made Vandortuzumab Vedotin benchmark antibody (Whole mAb ADC, anti-STEAP1 therapeutic antibody, Anti-PRSS24/STEAP Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-INN-1044
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-made Vandortuzumab Vedotin benchmark antibody (Whole mAb ADC, anti-STEAP1 therapeutic antibody, Anti-PRSS24/STEAP Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Vandortuzumab vedotin (INN; development code RG745) is a humanized monoclonal antibody designed for the treatment of cancer.[1][2]
| Products Name (INN Index) | Pre-Made Vandortuzumab Vedotin Biosimilar, Whole Mab Adc, Anti-Steap1 Antibody: Anti-PRSS24/STEAP therapeutic antibody Drug Conjugate |
|---|---|
| INN Name | vandortuzumab vedotin |
| Target | STEAP1 |
| Format | Whole mAb ADC |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 – kappa |
| VD LC | IgG1 – kappa |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Roche,?F. Hoffmann-La?Roche Ltd. (Basel Switzerland) / Genentech?Inc. (S. San Francisco CA USA) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | STEAP1 |
| Package |
Previous slide
Next slide
